Comparing two forms of targeted therapy for HER2-positive early breast cancer
Part of Cancer clinical trials.
This trial compares two ways of giving targeted therapy (Pyrotinib plus Trastuzumab) to treat HER2-positive early breast cancer: one is injected under the skin, the other is given through a vein. The goal is to see if the under-the-skin injection works as well and may be more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women aged 18 to 75 who are starting breast cancer treatment for the first time.
- Your cancer is HER2 positive (a certain type of protein is present on cancer cells).
- Your cancer is early stage (has not spread far) or locally advanced (may have spread to nearby lymph nodes but not to distant organs).
- You are able to perform daily activities with little or no help (ECOG score 0-1).
- You plan to have surgery to remove the breast tumor, such as a lumpectomy or mastectomy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a sequence of targeted therapy drugs for HER2-positive advanced breast cancer that has spread or cannot be removed by surgery. It aims to see if starting with trastuzumab rezetecan, followed by pyrotinib and trastuzumab plus capecitabine, helps control the cancer.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests if a newer drug, Trastuzumab Rezetecan, works as well as an approved drug, Trastuzumab Deruxtecan, when given before surgery for HER2-positive breast cancer. It aims to see which one helps shrink tumors more effectively.
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.